Therapeutic Raaas

RAS Oncoproteins Therapeutic Vulnerabilities

Ras Proteins: Their role in cancer and approaches to develop therapeutics

Anti-EGFR therapy for RAS wild-type left-sided colorectal cancer

CAPRI 2-GOIM: advancing precision therapy for RAS/BRAF wild type tumors

RAS Oncoproteins Therapeutic Vulnerabilities

"Your Behaviour Won't Be The Same" | Dr. Andrew Huberman (Stanford Neuroscientist)

Neurologic Music Therapy - Stroke Rehabilitation (MedRhythms)

Developing Therapies for Ras-driven Cancers

The Society for Translational Oncology

Novel Targets: PIKfyve, RAS, the epigenome & PROTAC therapy

VJHemOnc – Video Journal of Hematology & HemOnc

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

Targeted Oncology

Pharmacology: Drugs for Heart Failure, Animation

Alila Medical Media

RAS Gait Training

BRAF and RAS Mutation Status in Colorectal Cancer

Dr. Andrew Huberman on Reticular Activating System (RAS)

Targeting Ras-like proteins: a novel approach for antifungal therapy

Duke Clinical Research Institute

Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Bevacizumab or EGFR antibodies

Tools for Discovery of new K-Ras Therapeutics

Reaction Biology

Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - EGFR antibodies are mandatory

Deciphering RAS/MAPK signalling in cancer

Is front-line anti-EGFR therapy essential in RAS-WT mCRC?